We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Omnicell (OMCL) Moves 4.9% Higher: Will This Strength Last?
Read MoreHide Full Article
Omnicell (OMCL - Free Report) shares rallied 4.9% in the last trading session to close at $133.08. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 3.9% loss over the past four weeks.
Omnicell recorded a strong price increase on optimism surrounding its rumored acquisition deal by Baxter, a global medical technology company focused on renal and hospital products. According to a Seeking Alpha article of Mar 11, the company received a new $150/share takeover offer from Baxter. As per the article, Street Insider has first come up with this news and according to them, the takeover discussion is still going on between both the companies.
Further, last week Omnicell’s Central Pharmacy Dispensing Service got selected by Christ Hospital Health Network to enhance the latter’s medication inventory management. This has resulted in a steady rise in the stock price over the past few trading sessions.
Price and Consensus
This Omnicell Inc. Is expected to post quarterly earnings of $0.67 per share in its upcoming report, which represents a year-over-year change of +1.5%. Revenues are expected to be $245.35 million, up 6.8% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Omnicell, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on OMCL going forward to see if this recent jump can turn into more strength down the road.
Image: Bigstock
Omnicell (OMCL) Moves 4.9% Higher: Will This Strength Last?
Omnicell (OMCL - Free Report) shares rallied 4.9% in the last trading session to close at $133.08. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 3.9% loss over the past four weeks.
Omnicell recorded a strong price increase on optimism surrounding its rumored acquisition deal by Baxter, a global medical technology company focused on renal and hospital products. According to a Seeking Alpha article of Mar 11, the company received a new $150/share takeover offer from Baxter. As per the article, Street Insider has first come up with this news and according to them, the takeover discussion is still going on between both the companies.
Further, last week Omnicell’s Central Pharmacy Dispensing Service got selected by Christ Hospital Health Network to enhance the latter’s medication inventory management. This has resulted in a steady rise in the stock price over the past few trading sessions.
Price and Consensus
This Omnicell Inc. Is expected to post quarterly earnings of $0.67 per share in its upcoming report, which represents a year-over-year change of +1.5%. Revenues are expected to be $245.35 million, up 6.8% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Omnicell, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on OMCL going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank 3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>